Volume 27, Number 4—April 2021
Dispatch
Analysis of Asymptomatic and Presymptomatic Transmission in SARS-CoV-2 Outbreak, Germany, 2020
Table 2
Clinical symptoms of source case | No. contacts tested positive or experienced respiratory symptoms | Total no. contacts | SAR, % | RR (95% CI) |
---|---|---|---|---|
Household contacts SARlab | ||||
Asymptomatic | 0 | 4 | 0 | Reference |
Symptomatic, phase not specified or both† | 4 | 28 | 14.3 | 0.8 (0.09–∞) |
Total |
4 |
32 |
12.5 |
|
Household contacts SARres | ||||
Asymptomatic | 0 | 7 | 0 | Reference |
Symptomatic, phase not specified or both | 12 | 35 | 34.3 | 3.4 (0.56–∞) |
Total |
12 |
42 |
28.6 |
|
Other contacts SARlab | ||||
Asymptomatic cases | 0 | 22 | 0 | Reference |
Symptomatic, phase not specified or both | 3 | 25 | 12.0 | 3.4 (0.36–∞) |
Symptomatic, presymptomatic phase only | 15 | 72 | 20.8 | 6.5 (1.1–∞) |
Symptomatic, symptomatic phase only | 2 | 29 | 6.9 | 1.8 (0.14–∞) |
Total |
20 |
148 |
13.5 |
|
Other contacts SARres | ||||
Asymptomatic cases | 2 | 52 | 3.8 | Reference |
Symptomatic, phase not specified or both | 4 | 22 | 18.2 | 4.7 (0.68–52) |
Symptomatic, presymptomatic phase only | 22 | 67 | 32.8 | 8.5 (2.1–75) |
Symptomatic, symptomatic phase only | 1 | 29 | 3.5 | 0.90 (0.02–17) |
Total | 29 | 170 | 17.1 |
*RR relative risk; SAR, secondary attack rate; SARlab secondary attack rate for laboratory-confirmed SARS-CoV-2–positive contact persons; SARres, secondary attack rate for contact persons who experienced respiratory symptoms after contact. †The phase in which the contact occurred was not specified, or contact occurred in both phases.
1These first authors contributed equally to this article.
Page created: February 18, 2021
Page updated: March 18, 2021
Page reviewed: March 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.